DEVELOPMENTS IN MUCOSAL INFLUENZA-VIRUS VACCINES

Immunogenicity and efficacy of aerosol inactivated split influenza vir us vaccines, which are threefold the strength of the vaccines for pare nteral use, and cold-adapted reassortant live influenza virus vaccines were evaluated. Mucosal immune responses were evaluated by quantifyin g specific IgA antibody of the nasal swab solution, and systemic immun e responses were evaluated by determining serum haemagglutination inhi bition antibody levels. Efficacy of the aerosol inactivated vaccine wa s evaluated by a challenge test using live vaccine virus. It was concl uded that mucosally administered inactivated influenza virus vaccine s timulated systemic and mucosal immune responses more strongly than liv e influenza virus vaccine and manifested a much stronger booster effec t than live vaccine. Mucosal administration of inactivated influenza v irus vaccine was effective in preventing infection by live vaccine vir us.